MedPath

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1
Recruiting
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
Registration Number
NCT06030258
Lead Sponsor
InxMed (Shanghai) Co., Ltd.
Brief Summary

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).

Detailed Description

This study consists of 2 parts: 1) Phase Ib-Dose Confirmation part: To assess the PK parameters, safety and recommended phase II dose (RP2D) of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug), platinum (carboplatin is proposed as the combination drug) and etoposide as the first-line treatment in ES-SCLC. 2) Phase II-Dose Expansion part: To assess the antitumor efficacy, safety and tolerability in the experimental group of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to the control group of Tislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupIN10018IN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
Control groupEtoposideTislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC
Experimental groupTislelizumabIN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
Experimental groupEtoposideIN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
Control groupCarboplatinTislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC
Experimental groupCarboplatinIN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
Control groupTislelizumabTislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC
Primary Outcome Measures
NameTimeMethod
To identify the Recommended phase II dose (RP2D) of IN10018 in combination with Tislelizumab, Carboplatin and Etoposide in first-line ES-SCLC.Up to 3 years

Evaluate proportion of patients suffered with AEs defined as dose-limited toxicities (DLTs) per protocol; and RP2D will be determined per the incidence of AEs defined as DLTs.

Progress free survival (PFS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR based on RECIST 1.1Up to 3 years

Defined as the time from randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

Secondary Outcome Measures
NameTimeMethod
Objective response rate (ORR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1.Up to 3 years

Defined as the proportion of subjects with complete response (CR) or partial response (PR).

PK: AUC of IN10018 following single dose administration and at steady stateUp to 3 years

Area under the concentration-time curve (AUC)

Duration of objective response (DOR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1.Up to 3 years

Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

Number of patients with adverse eventUp to 3 years

The number of participants who experienced AEs is presented.

PK: Cmax of IN10018 following single dose administration and at steady stateUp to 3 years

Maximum concentration (Cmax)

PK: Ctrough of IN10018 following single dose administration and at steady stateUp to 3 years

Trough concentration (Ctrough)

PK: Tmax of IN10018 following single dose administration and at steady stateUp to 3 years

Time to Cmax (Tmax)

PK: Vd/F of IN10018 following single dose administration and at steady stateUp to 3 years

Apparent volume of distribution (Vd/F)

PFS of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per investigator based on RECIST 1.1Up to 3 years

Defined as the time from randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

Disease Control Rate (DCR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1Up to 3 years

Defined as the proportion of patients with CR, PR, or stable disease (SD).

PK: t1/2 of IN10018 following single dose administration and at steady stateUp to 3 years

Elimination half-life (t1/2)

PK: CL/F of IN10018 following single dose administration and at steady stateUp to 3 years

apparent clearance (CL/F)

Overall survival (OS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC.Up to 3 years

Defined as the time from randomization to the date of death due to any cause.

Trial Locations

Locations (3)

Shandong Province Cancer Hospital

🇨🇳

Jinan, China

Tianjin Medical University Cancer Institute & Hospital

🇨🇳

Tianjin, China

Henan Provincial People's Hospital

🇨🇳

Zhengzhou, China

© Copyright 2025. All Rights Reserved by MedPath